Share Price:

APNASPENAspen Pharmacare Hldgs20903-171 (-0.81%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen Matrix Release

Aspen Pharmacare Holdings Limited (“Aspen”) and Matrix Laboratories Limited (“Matrix”) of the Republic of India, would like to announce the divestment of the existing joint ventures relating to the two chemical-manufacturing entities, Fine Chemicals Corporation (Proprietary) Limited (“FCC”) in Cape Town, South Africa and Astrix Laboratories (“Astrix”) Limited in Hyderabad, India. Aspen will acquire 50%… Continue reading Aspen Matrix Release

Aspen establishes its international platform for future growth

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, is pleased to announce positive results for the year ended 30 June 2008. The Group delivered sustained growth from its existing bases in South Africa, Australia and Asia. A series of significant transactions were concluded to expand the Group’s footprint into Latin America,… Continue reading Aspen establishes its international platform for future growth

Revision of Terms of Aspen`s Investment in Strides` Latin American Operations

Further to the announcement made on 20 November 2007, Aspen is pleased to announce that its wholly owned subsidiary, Aspen Global Incorporated (“Global”) has agreed revised terms with Strides Arcolab Limited (“Strides”), a pharmaceutical company registered in the Republic of India, in respect of certain aspects of Global’s acquisition of an interest in Strides’ Latin… Continue reading Revision of Terms of Aspen`s Investment in Strides` Latin American Operations

Aspen Businesses in Licensing Deal With GSK

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced today that it has entered into licensing and supply agreements with leading multinational pharmaceutical corporation, GlaxoSmithKline (“GSK”). In terms of the agreements Aspen will license intellectual property and supply finished dosage form pharmaceuticals to GSK through Aspen Group companies including Onco Therapies Limited (“OTL”),… Continue reading Aspen Businesses in Licensing Deal With GSK

Aspen Invests R2.7 Billion in Expanding Global Business

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited (Apn) has announced an investment by its offshore subsidiary, Aspen Global Incorporated, of GBP 170 million (approximately R2.7 billion) for the acquisition of four pharmaceutical products from GlaxoSmithKline (GSK). Aspen Global has acquired the intellectual property rights to the branded pharmaceuticals Eltroxin, Imuran, Lanoxin and Zyloric for… Continue reading Aspen Invests R2.7 Billion in Expanding Global Business

Aspen wins significant portion of ARV tender

In addition to maintaining the supply contract for existing tender items, Aspen has also secured volumes for two new products, Aspen Efavirenz and Tenofivir. Tenofivir is a key new molecule to the ARV tender. Increased usage is anticipated over the tender period. Aspen secured more than 50% by volume of the entire ARV tender based… Continue reading Aspen wins significant portion of ARV tender

Shelys Africa Limited

Aspen Pharmacare Holdings Limited is pleased to announce the conclusion of a deal for the acquisition of 60% of the share capital of Shelys Africa Limited, with operations in East and Central Africa with effect from 01 May 2008. Shelys Africa Limited is the holding company of a group of East African pharmaceutical companies (“the… Continue reading Shelys Africa Limited

Motivation, direction and structure!

After my interview with him it once again dawned on me how important it is to enjoy what you do; to have a passion for it; to be motivated! In fact, when I carefully reflect on all the interviews with great leaders the recipe for success becomes clearer and clearer: You have to have motivation,… Continue reading Motivation, direction and structure!

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.